Cancer Treatment Reviews
Volume 24, Issue 1 , Pages 55-67 , February 1998

Immunotherapy and breast cancer

  • T.A. Plunkett

      Affiliations

    • Corresponding Author InformationCorrespondence: T. A. Plunkett, ICRF Immunotherapy Laboratory, Guy's Hospital, London SE1 9RT, U.K.
    • ,
  • D.W. Miles

References 

  1. Coley W. The treatment of malignant tumors by repeated inoculations of erysipelas: with a report of ten original cases. Am J Med Sci. 1893;105:487–511
  2. Coley Nauts H, Fowler G, Bogatko F. A review of the influence of bacterial infection and of bacterial products (Coley's toxins) on malignant tumors in man. Acta Med Scand. 1953;274-7:29–97 (Suppl.)
  3. Heberman R, Nunn M, Larvin D. Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic and allogeneic tumours. I: distribution of reactivity and specificity. Int J Cancer. 1975;16:216–229
  4. Kiessling R, Klein E, Wigzell H. “Natural killer” cells in the mouse. I: cytotoxicity cells with specificity for mouse Moloney leukemic cells. In: Specificity and distribution according to genotype. second edition. Eur J Immunol. 5:1975;p. 112–117
  5. Becker S, Fenyo E, Klein E. The “natural killer” cell in the mouse does not require H-2 homology and is not directed against type or group specific antigens of murine C viral proteins. Eur J Immunol. 1976;6:882–885
  6. Trinchieri G. Biology of natural killer cells. Adv Immunol. 1989;47:187–376
  7. Moretta L, Mingari M, Pende D, et al.  The molecular basis of natural killer (NK) cell recognition and function. J Clin Immunol. 1996;16:243–253
  8. Steinman R. The dendritic cell and its role in immunogenicity. Ann Rev Immunol. 1991;9:271–296
  9. Porgador A, Gilboa E. Bone marrow-generated dendritic cells pulsed with a class I-restricted peptide are potent inducers of cytotoxic T lymphocytes. J Exp Med. 1995;182:255–260
  10. Lutz M, Girolomoni G, Ricciardi-Castagnoli P. The role of cytokines in functional regulation and differentiation of dendritic cells. Immunobiology. 1996;195:431–455
  11. Cella M, Scheidegger D, Palmer-Lehmann KEA. Ligation of CD40 on dendritic cells triggers production of high levels of IL12 and enhances T cell stimulatory capacity: T-T help via APC activation. J Exp Med. 1996;184:747–752
  12. Heufler C, Koch F, Stanzl U, et al.  Interleukin-12 is produced by dendritic cells and mediates TH1 development as well as interferon gamma production by TH1 cells. Eur J Immunol. 1996;26:659–668
  13. Winzler C, Rovere P, Resigno M, et al.  Maturation stages of mouse dendritic cells in growth factor-dependent long-term cultures. J Exp Med. 1997;185:317–328
  14. Swain S. T cell subsets and the recognition of MHC class. Immunol Rev. 1983;74:129–142
  15. Bjorkman P, Saper M, Samraoui B, et al.  Structure of the human class I histocompatibility antigen HLA-A2. Nature. 1987;329:506–512
  16. Brown J, Jardetzky T, Gorga J, et al.  Three-dimensional structure of the human class II histocompatibility antigen HLA-DR1. Nature. 1993;364:33–39
  17. Madden D. The three-dimensional structure of peptide-MHC complexes. Ann Rev Immunol. 1995;13:587–662
  18. Krensky A, Reiss C, Mier J, et al.  Long-term human cytolytic T-cell lines allospecific for HLA-DR6 antigen are OKT4+. In: second edition. Proc Natl Acad Sci USA. 79:1982;p. 2365–2369
  19. Morrison L, Lukacher A, Braciale V, et al.  Differences in antigen presentation to MHC class I and class II-restricted influenza virus-specific cytolytic T lymphocyte clones. J Exp Med. 1986;163:903–912
  20. Townsend A, Rothbard J, Gotch F, et al.  The epitopes of influenza nucleoprotein recognized by cytotoxic T lymphocytes can be defined with short synthetic peptides. Cell. 1986;44:959–965
  21. Lechler R, Aichinger G, Lightstone L. The endogenous pathway of MHC class II antigen presentation. Immunol Rev. 1996;151:51–79
  22. Jondal M, Schirmbeck R, Reimann J. MHC class I-restricted CTL responses to exogenous antigens. Immunity. 1996;5:295–302
  23. Viola A, Lanzavecchia A. T cell activation determined by T cell receptor number and tunable thresholds. Science. 1996;273:104–106
  24. Jenkins M, Schwartz R. Antigen presentation by chemically modified splenocytes induces antigen-specific T cell unresponsiveness in vitro and in vivo. J Exp Med. 1987;165:302–313
  25. Meuller D, Jenkins M, Schwartz R. Clonal expansion versus functional clonal inactivation: a co-stimulatory signalling pathway determines the outcome of T cell antigen receptor occupancy. Ann Rev Immunol. 1989;7:445–492
  26. Miller J. Lymphocyte interactions in immune responses. Int Rev Cytol. 1972;33:77–130
  27. Clark E, Ledbetter J. How B and T cells talk to each other. Nature. 1994;367:425–428
  28. Kirkwood J. Biologic therapy with interferon alpha and beta: clinical applications—melanoma. In:  De Vita VJ,  Hellman S,  Rosenberg S editor. Biologic Therapy of Cancer: Principles and Practice. Philadelphia, PA: Lippincott; 1995;p. 388–411
  29. Kirkwood J, Strawdermann M, Ernstoff M, et al.  Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol. 1996;14:7–17
  30. Cole B, Gelber R, Kirkwood J, et al.  Quality-of-life-adjusted survival analysis of interferon alfa-2b adjuvant treatment of high-risk resected cutaneous melanoma: an Eastern Cooperative Oncology Group study. J Clin Oncol. 1996;14:2666–2773
  31. Wirth M. Immunotherapy for metastatic renal cell carcinoma. Urol Clin N Am. 1993;20:283–295
  32. Neidhart J, Anderson S, Harris J, et al.  Vinblastine fails to improve response of renal cancer to interferon alfa-n1: high response rate in patients with pulmonary metastases. J Clin Oncol. 1991;9:832–836
  33. Rosenberg S, Lotze M, Muul L, et al.  A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med. 1987;316:889–897
  34. Law T, Motzer R, Mazumdar M, et al.  Phase III randomized trial of interleukin-2 with or without lymphokine-activated killer cells in the treatment of patients with advanced renal cell cancer. Cancer. 1995;76:824–832
  35. Fyfe G, Fisher R, Rosenberg S, et al.  Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol. 1995;13:688–696
  36. Fyfe G, Fisher R, Rosenberg S, et al.  Long-term response data for 255 patients with metastatic renal cell carcinoma treated with high-dose recombinant interleukin-2 therapy. J Clin Oncol. 1996;14:2410–2411
  37. Motzer R, Bander N, Nanus D. Renal-cell carcinoma. N Engl J Med. 1996;335:865–875
  38. Mastrangelo M, Maguire H, Sato T, et al.  Active specific immunization in the treatment of patients with melanoma. Semin Oncol. 1996;23:773–781
  39. Boussiotis V, Freeman G, Gribben J, et al.  The role of B7-1/B7-2:CD28/CTLA-4 pathways in the prevention of anergy, induction of productive immunity and down-regulation of the immune response. Immunol Rev. 1996;154:5–26
  40. Townsend S, Allison J. Tumour rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. Science. 1993;259:368–371
  41. Dranoff G, Jaffee E, Lazenby A, et al.  Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. In: second edition. Proc Natl Acad Sci USA. 90:1993;p. 3539–3543
  42. Rosenberg S, Anderson W, Blaese R, et al.  Immunisation of cancer patients using autologous cancer cells modified by the insertion of the gene for interleukin-2. Human Gene Ther. 1992;3:75–90
  43. Boon T, Gajewski T, Coulie P. From defined human tumor antigens to effective immunization?. Immunol Today. 1995;16:334–336
  44. Van Pel A, Van der Bruggen P, Coulie P, et al.  Genes coding for tumor antigens recognized by cytolytic T lymphocytes. Immunol Rev. 1995;145:229–250
  45. Hsu F, Benike C, Fagnoni F, et al.  Vaccination of patients with B cell lymphoma using autologous antigen-pulsed dendritic cells. Nature Med. 1996;2:52–58
  46. Romani N, Lanzavecchia A. Proliferating dendritic cell progenitors in human blood. J Exp Med. 1994;180:83–93
  47. Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony stimulating factor plus interleukin-4 and downregulated by tumour necrosis factor alpha. J Exp Med. 1994;179:1109–1118
  48. Barratt-Boyes S, Watkins S, Finn O. In vivo migration of dendritic cells differentiated in vitro: a chimpanzee model. J Immunol. 1997;158:4543–4547
  49. Wang M, Bronte V, Chen P, et al.  Active immunotherapy of cancer with a nonreplicating recombinant fowlpox virus encoding a model tumor-associated antigen. J Immunol. 1995;154:4685–4692
  50. Bronte V, Tsung K, Rao J, et al.  IL-2 enhances the function of recombinant poxvirus-based vaccines in the treatment of established pulmonary metastases. J Immunol. 1995;154:5482–5492
  51. Chamberlain R, Carroll M, Bronte V, et al.  Costimulation enhances the active immunotherapy effect of recombinant anti-cancer vaccines. Cancer Res. 1996;56:2832–2836
  52. Murata K, Garcia Sastre A, Tsuji M, et al.  Characterization of in vitro primary and secondary CD8+ T cell responses induced by recombinant influenza and vaccinia viruses. Cell Immunol. 1996;173:96–107
  53. Battegay M, Moskophidis D, Waldner H, et al.  Impairment and delay of neutralizing antiviral antibody responses by virus-specific cytotoxic T cells. [published erratum appears in J Immunol 1994;152:1635] J Immunol. 1993;151:5408–5415
  54. Deng Y, Yewdell J, Eisenlohr L, et al.  MHC affinity, peptide liberation, T cell repertoire, and immunodominance all contribute to the paucity of MHC class-I restricted peptides recognized by anti-viral CTL. J Immunol. 1997;158:1507–1515
  55. Wolff J, Malone R, Williams P, et al.  Direct gene transfer into muscle muscle in vivo. Science. 1990;247:1465–1468
  56. Jioa S, Williams P, Berg R, et al.  Direct gene-transfer in nonhuman primate myofibres in vivo. Human Gene Ther. 1992;3:21–33
  57. Ulmer J, Deck R, DeWitt C, et al.  Protective immunity by intramuscular injection of low doses of influenza virus DNA vaccines. Vaccine. 1994;12:1541–1544
  58. Conry R, Lobuglio A, Loechel F, et al.  A carcinoembryonic antigen polynucleotide vaccine has in vivo antitumour activity. Gene Ther. 1995;2:59–65
  59. Winter G, Milstein C. Man-made antibodies. Nature. 1991;349:293–299
  60. Jakobovits A, Grenn L, Hardy M, et al.  Production of antigen-specific human antibodies from mice engineered with human heavy and light chain YACs. Ann NY Acad Sci. 1995;764:525–535
  61. Renner C, Jung W, Sahin U, et al.  Cure of xenografted human tumors by bispecific monoclonal antibodies and human T cells. Science. 1994;264:833–835
  62. Leonard P, Begent R. Immunotherapy options for colorectal cancer. Oncol Practice. 1997;8–11
  63. Begent R, Verhaar M, Chester K, et al.  Clinical evidence of efficient tumour targeting based on single chain Fv antibody selected from a combinatorial library. Nature Med. 1996;2:979–983
  64. Whiteside T, Miescher S, Hurlimann J, et al.  Separation, phenotyping and limiting dilution analysis of T lymphocytes infiltrating human solid tumors. Int J Cancer. 1986;37:803–811
  65. Wei W-Z, Heppner G. Breast Cancer Immunology. Cancer Treat Res. 1996;83:395–410
  66. Heo D, Whiteside T, Johnson J, et al.  Long-term interleukin-2 dependent growth and cytotoxicity of human tumor-infiltrating lymphocytes from human squamous cell carcinomas of the head and neck. Cancer Res. 1987;47:6353–6362
  67. Venetsanakos E, Beckman I, Bradley J, et al.  High incidence of interleukin 10 mRNA but not interleukin 2 mRNA detected in human breast tumours. Br J Cancer. 1997;75:1826–1830
  68. Coventry B, Weeks S, Heckford S, et al.  Lack of IL-2 cytokine expression despite IL-2 messenger mRNA transcription in tumor-infiltrating lymphocytes in primary breast carcinoma: selective expression of early activation markers. J Immunol. 1996;156:3486–3492
  69. Schondorf T, Engel H, Lindemann C, et al.  Cellular characteristics of peripheral blood lymphocytes and tumour-infiltrating lymphocytes in patients with gynaecological tumours. Cancer Immunol Immunother. 1997;44:88–96
  70. Becker J, Czerny C, Brocker E. Maintenance of clonal anergy by endogenously produced IL-10. Int Immunol. 1994;6:1605–1612
  71. Beissert S, Hosoi J, Grabbe S, et al.  IL-10 inhibits tumor antigen presentation by epidermal antigen-presenting cells. J Immunol. 1995;154:1280–1286
  72. Gendler S, Lancaster C, Taylor-Papadimitriou J, et al.  Molecular cloning and expression of the human tumour-associarted polymorphic epithelial mucin. J Biol Chem. 1990;265:15286–15293
  73. Swallow D, Gendler S, Griffith B, et al.  The human tumour-associated epithelial mucins are coded for by an expressed hypervariable gene locus PEM. Nature. 1987;328:82–84
  74. Braga V, Pemberton L, Duhig T, et al.  Spatial and temporal expression of an epithelial mucin, MUC1, during mouse development. Development. 1992;115:427–437
  75. Wesseling J, Vanderwalk S, Vos H, et al.  Episialin (MUC1) overexpression inhibits integrin-mediated cell-adhesion to extracellular matrix components. J Cell Biol. 1995;129:255–265
  76. Miller S, Codington J, Klein G. Further studies on the relationship between allotransplantability in the presence of the cell surface glycoprotein epiglycanin in the TA3-MM mouse mammary carcinoma ascites cell. J Natl Cancer Inst. 1982;68:981–988
  77. Graham R, Burchell J, Taylor-Papadimitriou J. The polymorphic epithelial mucin: potential as an immunogen for a cancer vaccine. Cancer Immunol Immunother. 1996;42:71–80
  78. Brockhausen I, Yang J-M, Burchell J, et al.  Mechanisms underlying aberrant glycosylation of MUC1 mucin in breast cancer cells. Eur J Biochem. 1995;233:607–618
  79. Ioannides C, Fisk B, Jerome K, et al.  Cytotoxic T cells from ovarian malignant tumors can recognize polymorphic epithelial mucin core peptides. J Immunol. 1993;151:3693–3703
  80. Jerome K, Barnd D, Bendt K, et al.  Cytotoxic T-lymphocytes derived from patients with breast adenocarcinoma recognize an epitope present on the protein core of a mucin molecule preferentially expressed by malignant cells. Cancer Res. 1991;51:2908–2916
  81. Barnd D, Lan M, Metzgar R, et al.  Specific, major histocompatibility complex-unrestricted recognition of tumor-associated mucins by human cytotoxic T cells. In: second edition. Proc Natl Acad Sci USA. 86:1989;p. 7159–7163
  82. Takahashi T, Makiguchi Y, Hinoda Y, et al.  Expression of MUC1 on myeloma cells and induction of HLA-unrestricted CTL against MUC1 from a multiple myeloma patient. J Immunol. 1994;153:2102–2109
  83. Finn O, Jerome K, Henderson R, et al.  MUC1 epithelial tumor mucin-based immunity and cancer vaccines. Immunol Rev. 1995;145:61–89
  84. Fontenot J, Tjandra N, Bu D, et al.  Biophysical characterization of one-, two-, and three tandem repeats of human mucin (MUC1) protein core. Cancer Res. 1993;53:5386–5392
  85. Burchell J, Gendler S, Taylor-Papadimitriou J, et al.  Development and characterisation of breast cancer reactive monoclonal antibodies directed to the core protein of the human milk mucin. Cancer Res. 1987;47:5476–5482
  86. Kotera Y, Fontenot J, Pecher G, et al.  Humoral immunity against a tandem repeat epitope of human mucin MUC-1 in sera from breast, pancreatic and colon cancer patients. Cancer Res. 1994;54:2856–2860
  87. Gourevitch M, von Mensdorff-Pouilly S, Litvinov S, et al.  Polymorphic epithelial mucin (MUC1)-containing circulating immune complexes in carcinoma patients. Br J Cancer. 1995;72:934–938
  88. von Mensdorff-Pouilly S, Gourevitch M, Kenemans P, et al.  Humoral immune responses to polymorphic epithelial mucin (MUC-1) in patients with benign and malignant breast tumours. Eur J Cancer. 1996;32A:1325–1331
  89. Strominger J. Peptide vaccination against cancer?. Nature Med. 1995;1:1140
  90. Fung P, Longenecker B. Specific immunosuppressive activity of epiglycanin, a mucin-like glycoprotein secreted by a murine adenocarcinoma (TA3-HA). Cancer Res. 1991;51:1170–1176
  91. Lalani E-N, Berdichevsky F, Boshell M, et al.  Expression of the gene encoding for a human mucin in mouse mammary tumor cells can affect their immunogenicity. J Biol Chem. 1991;266:15420–15426
  92. Graham R, Stewart L, Peat N, et al.  MUC1-based immunogens for tumour therapy: development of murine model systems. Tumour Targeting. 1995;1:211–221
  93. Jerome K, Domenech N, Finn O. Tumor-specific cytotoxic T cell clones from patients with breast and pancreatic adenocarcinoma recognize EBV-immortalized B cells transfected with polymorphic epithelial mucin complementary DNA. J Immunol. 1993;151:1564–1570
  94. Pecher G, Finn O. Induction of cellular immunity in chimpanzees to human tumor-associated antigen mucin by vaccination with MUC-1 cDNA-transfected Epstein-Barr virus-immortalized autologous B cells. In: second edition. Proc Natl Acad Sci USA. 93:1996;p. 1699–1704
  95. Henderson R, Nimgoankar M, Watkins S, et al.  Human dendritic cells genetically engineered to express high levels of the human epithelial tumor antigen (MUC-1). Cancer Res. 1996;56:3763–3770
  96. Barratt-Boyes S. Making the most of mucin: a novel target for tumor immunotherapy. Cancer Immunol Immunother. 1996;43:142–151
  97. Gong J, Chen D, Kashiwaba M, et al.  Induction of antitumour activity by immunization with fusions of dendritic and carcinoma cells. Nature Med. 1997;3:558–561
  98. Ding L, Lalani E, Reddish M, et al.  Immunogenicity of synthetic peptides related to the core peptide sequence encoded by the human MUC1 gene: effect of immunisation on the growth of murine mammary adenocarcinoma cells transfected with the human MUC1 gene. Cancer Immunol Immunother. 1993;36:9–17
  99. Apostolopoulos V, Xing P-X, McKenzie I. Murine immune response to cells transfected with human MUC1: immunization with cellular and synthetic antigens. Cancer Res. 1994;54:5186–5193
  100. Apostolopoulos V, Pietersz G, Loveland B, et al.  Oxidative/reductive conjugation of mannan to antigen selects for T1 or T2 immune responses. In: second edition. Proc Natl Acad Sci USA. 92:1995;p. 10128–10132
  101. Xing P-X, Michael M, Apostolopoulos V, et al.  Phase I study of synthetic MUC1 peptides in breast cancer. Int J Oncol. 1995;6:1283–1289
  102. Goydos J, Elder E, Whiteside T, et al.  A phase I trial of a synthetic mucin peptide vaccine. In: Induction of specific immune reactivity in patients with adenocarcinoma. second edition. J Surg Res. 63:1996;p. 298–304
  103. Nakagomi H, Petersson M, Magnusson I, et al.  Decreased expression of the signal-transducing theta chains in tumor-infiltrating T-cells and NK cells of patients with colorectal carcinoma. Cancer Res. 1993;53:5610–5612
  104. Apostolopoulos V, Loevland B, Pietersz G, et al.  CTL in mice immunized with human MUC 1 are MHC-restricted. J Immunol. 1995;155:5089–5094
  105. Hareveuni M, Gautier C, Kieny M-P, et al.  Vaccination against tumour cells expressing breast cancer epithelial tumour antigens. In: second edition. Proc Natl Acad Sci USA. 87:1990;p. 9498–9502
  106. Acres R, Hareuveni M, Balloul J, et al.  Vaccinia virus MUC1 immunization of mice: immune response and protection against the growth of murine tumours bearing the MUC1 antigen. J Immunother. 1993;14:136–143
  107. Balloul J, Acres R, Geist M, et al.  Recombinant MUC1 vaccinia virus: a potential vector for immunotherapy of breast cancer. Cell Mol Biol. 1994;40:49–59
  108. Scholl S, Acres B, Kieny M, et al.  The polymorphic epithelial mucin (MUC1): a phase I clinical trial testing the tolerance and immunogenicity of a vaccinia virus-MUC1-IL2 construct in breast cancer. Breast Cancer Res Treat. 1997;46:268; (abstr)
  109. Itzkowitz S, Bloom E, Kokal W, et al.  Sialosyl-Tn: a novel mucin antigen associated with prognosis in colorectal cancer patients. Br J Cancer. 1990;66:1960–1966
  110. Chun M, Terata N, Kodami M, et al.  Expression of sialyl-Tn antigen is correlated with survival time of patients with gastric carcinomas. Eur J Cancer. 1993;29A:1820–1823
  111. Kobayashi H, Terao T, Kawashima Y. Serum sialyl-Tn as an independent predictor of poor prognosis in patients with epithelial ovarian cancer. J Clin Oncol. 1992;10:95–101
  112. Longenecker B, Reddish M, Miles D, et al.  Synthetic tumor-associated sialyl-Tn antigen as an immunotherapeutic cancer vaccine. Vaccine Res. 1993;2:151–162
  113. Miles D, Happerfield L, Smith P, et al.  Expression of sialyl-Tn predicts the utility of adjuvant chemotherapy in node positive breast cancer. Br J Cancer. 1994;70:1272–1275
  114. Sutherland R. Cell and environment interactions in tumour microregions: the multicell spheroid model. Science. 1988;240:177–184
  115. Fung P, Madej M, Koganty K, et al.  Active specific immunotherapy of a murine mammary adenocarcinoma using a synthetic tumour-associated glycoconjugate. Cancer Res. 1990;50:4308–4314
  116. Singhal A, Fohn M, Hakomori S. Induction of a N-acetylgalactosamine-O-serine/threonine (Tn) antigen-mediated cellular immune response for active specific immunotherapy in mice. Cancer Res. 1991;51:1406–1411
  117. MacLean G, Miles D, Rubens R, et al.  Enhancing the effect of THERATOPE STn-KLH cancer vaccine patients with metastatic breast cancer by pre-treatment with low-dose intravenous cyclophosphamide. J Immunother. 1996;19:309–316
  118. MacLean G, Reddish M, Koganty R, et al.  Antibodies against mucin-associated sialyl-Tn epitopes correlate with survival of metastatic adenocarcinoma patients undergoing active specific immunotherapy with synthetic STn vaccine. J Immunol Emphasis Tumor Immunol. 1996;19:59–68
  119. Hird V, Maraveyas A, Snook D, et al.  Adjuvant therapy of ovarian cancer with radioactive monoclonal antibody. Br J Cancer. 1993;68:403–406
  120. Kosmas C, Epenetos A, Courtenay-Luck N. Activation of cellular immunity after intracavitary monoclonal antibody therapy of ovarian cancer. Cancer. 1994;73:3000–3010
  121. Riethmuller G, Schneider-Gadicke E, Schlimok G, et al.  Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma. Lancet. 1994;343:1177–1183
  122. Kamanski M, Zasadny K, Francis I, et al.  Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma. J Clin Oncol. 1996;14:1974–1981
  123. Baselga J, Tripathy D, Mendelsohn J, et al.  Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol. 1996;14:737–744
  124. Toes R, Blom R, Offringa R, et al.  Functional deletion of tumor-specific CTLs induced by peptide vaccination can lead to the inability to reject tumours. J Immunol. 1996;156:3911–3918
  125. Livingston P, Wong G, Adhuri S, et al.  Improved survival in stage II melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside. J Clin Oncol. 1994;12:1036–1044
  126. Melief C, Offringa R, Toes R, et al.  Peptide-based cancer vaccines. Curr Opinion Immunol. 1996;8:651–657
  127. Hayward J, Carbone P, Heuson J, et al.  Assessment of response to therapy in advanced breast cancer. Cancer. 1977;39:1289–1294
  128. Ferrone S, Marincola F. Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance. Immunol Today. 1995;16:487–494
  129. Restifo N, Esquivel F, Kawakami Y, et al.  Identification of human cancers deficient in antigen processing. J Exp Med. 1993;177:265–272

PII: S0305-7372(98)90071-8

Cancer Treatment Reviews
Volume 24, Issue 1 , Pages 55-67 , February 1998

Article Tools